Trial Profile
An Expanded Access Protocol of Oral Rociletinib (CO-1686) as Epidermal Growth Factor Receptor (EGFR)-Directed Therapy for Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) With the T790M Resistance Mutation
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Rociletinib (Primary)
- Indications Non-small cell lung cancer
- Focus Expanded access; Therapeutic Use
- Sponsors Clovis Oncology [CEASED]
- 17 Mar 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 16 Sep 2015 New trial record